MedicaidCoverageMedium impact

22-340 Medication Trend Updates and Formulary Changes - 1st Quarter 2022

Q: Who is affected by this change?

This affects Health Net Family Medicine, Internal Medicine, Pain Management, Psychiatry, General Practice providers in CA on Medicaid plans.

Health Net·CA · Family Medicine, Internal Medicine, Pain Management +2 more·Pharmacy

Effective date

Not stated

We identified it

Jun 20, 2026

Days to comply

—

Summary

This policy update provides safety information about buprenorphine dental risks and updates the CalViva Health Medi-Cal Preferred Drug List for Q1 2022, carving out two new medications (Bylvay and Livmarli) for specialized cholestatic conditions. The changes primarily affect Medi-Cal providers in Fresno, Kings, and Madera counties in California.

Action Required

Action needed

Immediately: Providers prescribing buprenorphine must perform baseline dental evaluations and counsel patients about dental risks. Contact CalViva Health pharmacy services at 800-977-2273 for PDL questions. Update prescribing protocols to include dental history assessment and patient counseling for oral buprenorphine products.

Related policy hubs

Health Net policies CA policy changes Family Medicine Internal Medicine Pain Management Psychiatry General Practice